Literature DB >> 630689

The hemodynamic effects of intravenous tocainide in patients with heart disease.

R A Winkle, J L Anderson, F Peters, P J Meffin, R E Fowles, D C Harrison.   

Abstract

In order to evaluate its hemodynamic actions, tocainide, a new orally effective antiarrhythmic drug, was given intravenously over a 15 minute period to 12 patients with compensated left ventricular dysfunction. Doses were 0.5 (4 patients) or 0.75 (8 patients) mg/kg/min. Hemodynamics and drug plasma concentrations were measured at the end and 15 minutes after the end of the infusion. Tocainide infusion produced small but statistically significant increases in the pulmonary and systemic vascular resistance, aortic and pulmonary arterial pressure, and left and right ventricular end-diastolic pressure. There was no significant change in left ventricular dp/dt, heart rate, or cardiac index. In patients with compensated left ventricular dysfunction, tocainide produces a small rise in vascular resistance and arterial pressure. Overall cardiac function is maintained with a small increase in left ventricular end-diastolic pressure.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 630689     DOI: 10.1161/01.cir.57.4.787

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  4 in total

1.  Pharmacokinetics and haemodynamic effects of tocainide in patients with acute myocardial infarction complicated by left ventricular failure.

Authors:  B MacMahon; M Bakshi; P Branagan; J G Kelly; M J Walsh
Journal:  Br J Clin Pharmacol       Date:  1985-04       Impact factor: 4.335

2.  Haemodynamic effects of class I antiarrhythmic agents.

Authors:  V Legrand; P Collignon
Journal:  Drugs       Date:  1985       Impact factor: 9.546

Review 3.  Tocainide. A review of its pharmacological properties and therapeutic efficacy.

Authors:  B Holmes; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-08       Impact factor: 9.546

4.  Pharmacokinetics of tocainide in patients with severe renal failure.

Authors:  J Braun; F Sörgel; F Engelmaier; W P Gluth; U Gessler
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.